clinical trial · NCT05287113
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Incyte Biosciences International Sàrl·phase2·active not recruiting·n = 176
Head and Neck CancerRetifanlimabINCAGN02385INCAGN02390Placebo
brief summary
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
started
Nov 14, 2022
primary completion
Mar 14, 2025
completion
Jul 10, 2026
last updated
Mar 27, 2026
official title
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol